8-K
filed April 11, 2025, 7:59 PM ET
ticker SNPS
CIK 0000883241
other material
confidence high
sentiment neutral
materiality 0.40
Synopsys shareholders approve 1.6M share increase in employee equity plan and 2.2M share increase in ESPP
SYNOPSYS INC
- Stockholders approved an amendment to the 2006 Employee Equity Incentive Plan to increase authorized shares by 1,600,000; vote 120.2M for, 5.7M against.
- Stockholders approved the amended Employee Stock Purchase Plan, increasing shares by 2,200,000; vote 125.6M for, 450K against.
- All nine director nominees were elected, with vote tallies ranging from 108.2M to 125.4M for each nominee.
- Advisory vote on executive compensation passed 113.9M for, 11.1M against; KPMG ratified as auditor for fiscal 2025.
- A stockholder proposal on golden parachutes was not approved (48.4M for, 77.5M against).
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-25-079138
- form_type
- 8-K
- ticker
- SNPS
- cik
- 0000883241
- company_name
- SYNOPSYS INC
- filed_at
- 2025-04-11T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:51.588987+00:00
- generated_at
- 2026-05-23T16:43:16.594320+00:00
- sec_items
- ["5.02", "5.07", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.4
- calibrated_materiality_score
- 0.4
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-25-079138
- json_url
- https://secwatch.observer/filing/0001193125-25-079138.json
- markdown_url
- https://secwatch.observer/filing/0001193125-25-079138.md
- text_url
- https://secwatch.observer/filing/0001193125-25-079138.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/883241/000119312525079138/0001193125-25-079138-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/883241/000119312525079138/d836619d8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
CRM
Salesforce shareholders approve 34M share equity plan increase, extend term to 2036, all directors re-elected
Salesforce, Inc.
June 1, 2026, 4:43 PM ET
other_material
Items 5.07, 5.02, 9.01
same SEC item: 5.02, 5.07, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
BRANDYWINE OPERATING PARTNERSHIP, L.P.
Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP
BRANDYWINE OPERATING PARTNERSHIP, L.P.
June 1, 2026, 4:30 PM ET
other_material
Items 1.01, 2.03, 5.02, 5.07, 9.01
same SEC item: 5.02, 5.07, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
SIRI
Sirius XM shareholders approve 7.2M share increase in 2024 equity plan, elect directors
SIRIUS XM HOLDINGS INC.
June 1, 2026, 4:28 PM ET
other_material
Items 5.02, 5.07, 9.01
same SEC item: 5.02, 5.07, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
ESPR
Esperion shareholders approve 7M-share increase to 2022 equity incentive plan
Esperion Therapeutics, Inc.
June 1, 2026, 4:22 PM ET
other_material
Items 5.02, 5.07, 9.01
same SEC item: 5.02, 5.07, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
EMYB
Embassy Bancorp expands stock repurchase program by additional $5M
Embassy Bancorp, Inc.
June 1, 2026, 4:37 PM ET
other_material
Items 8.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
MXL
MaxLinear dismisses Grant Thornton, appoints KPMG as auditor for FY2026
MAXLINEAR, INC
June 1, 2026, 4:35 PM ET
other_material
Items 4.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
SMC
Summit Midstream Corporation announces inaugural $35 million stock repurchase program
Summit Midstream Corp
June 1, 2026, 4:31 PM ET
other_material
Items 7.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CTXR
Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned
Citius Pharmaceuticals, Inc.
June 1, 2026, 4:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.